SCHEMBL6898699

SCHEMBL6898699

CC(=NOCCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccc(-c2ccccc2)nc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PPARG P37231 14/20 1.00
FFAR1 O14842 6/20 0.52
CYP3A4 P08684 2/20 0.47
RXRA P19793 2/20 0.47
MEN1 O00255 1/20 0.46
ALDH1A1 P00352 1/20 0.46
TP53 P04637 1/20 0.46
CYP1A2 P05177 1/20 0.46
MAPT P10636 1/20 0.46
HPGD P15428 1/20 0.46
ALOX15 P16050 1/20 0.46
TSHR P16473 1/20 0.46
KMT2A Q03164 1/20 0.46
HSD17B10 Q99714 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
RARG P13631 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6898697 1.00 PPARG (1.00) PPARGFFAR1CYP3A4RXRAMEN1
SCHEMBL6898656 0.89 PPARG (0.81) PPARGFFAR1CYP3A4MEN1ALDH1A1
SCHEMBL6899309 0.89 PPARG (0.81) PPARGFFAR1CYP3A4MEN1ALDH1A1
SCHEMBL6934348 0.88 PPARG (0.78) PPARGFFAR1CYP3A4RXRAMEN1
SCHEMBL1131019 0.88 PPARG (0.78) PPARGFFAR1CYP3A4RXRAMEN1
SCHEMBL6902809 0.87 PPARG (0.77) PPARGFFAR1CYP3A4RXRAMEN1
SCHEMBL6902815 0.87 PPARG (0.77) PPARGFFAR1CYP3A4RXRAMEN1
Hydrochloric Acid SCHEMBL8446836 0.87 PPARG (0.77) PPARGFFAR1CYP3A4RXRAMEN1
SCHEMBL8309657 0.87 PPARG (0.76) PPARGFFAR1CYP3A4MEN1ALDH1A1
SCHEMBL8309658 0.87 PPARG (0.76) PPARGFFAR1CYP3A4MEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0919232-B1 Composition for use in the treatment and prevention of hyperuricemia SANKYO CO (JP) 2004-10-06 EP claimed
US-6353009-B1 TREATMENT OF GOUT WITH ANTIINFLAMMATORY AGENTS SANKYO COMPANY, LIMITED (JP) 2002-03-05 US claimed
EP-0919232-A1 Composition for use in the treatment and prevention of hyperuricemia Sankyo Company Limited (JP) 1999-06-02 EP claimed
EP-0708098-B1 Oxime derivatives, their preparation and their therapeutic use SANKYO CO (JP) 1999-03-03 EP claimed
EP-0708098-A1 Oxime derivatives, their preparation and their therapeutic use SANKYO COMPANY LIMITED (JP) 1996-04-24 EP claimed
EP-0919232-B1 Composition for use in the treatment and prevention of hyperuricemia SANKYO CO (JP) 2004-10-06 EP disclosed
EP-0916651-B1 PHENYLALKYLCARBOXYLIC ACID DERIVATIVES SANKYO CO (JP) 2003-10-15 EP disclosed
US-6353009-B1 TREATMENT OF GOUT WITH ANTIINFLAMMATORY AGENTS SANKYO COMPANY, LIMITED (JP) 2002-03-05 US disclosed
US-6150371-A WITH THE EXCEPTION OF TYPE I DIABETES; INHIBITS INVASION OF ORGAN TISSUE BY CYTOTOXIC LYMPHOCYTES; ADMINISTERING TO A MAMMAL AN ANTIAUTOIMMUNE DISEASE AGENT BEING AN INSULIN RESISTANCE REDUCING AGENT, ANTIDIABETIC, E.G., TROGLITAZONE SANKYO COMPANY, LIMITED (JP) 2000-11-21 US disclosed
US-6103907-A ALDOSE REDUCTASE INHIBITING ANTIDIABETIC AGENT SANKYO COMPANY, LIMITED (JP) 2000-08-15 US disclosed
EP-0953355-A1 REMEDY FOR AUTOIMMUNE DISEASES Sankyo Company, Limited (JP) 1999-11-03 EP disclosed
US-5972959-A Oxime derivatives, their preparation and their therapeutic use SANKYO COMPANY, LIMITED (JP) 1999-10-26 US disclosed
CN-1219927-A Phenylalkylcarboxylic acid derivatives SANKYO CO (JP) 1999-06-16 CN disclosed
EP-0919232-A1 Composition for use in the treatment and prevention of hyperuricemia Sankyo Company Limited (JP) 1999-06-02 EP disclosed
EP-0916651-A1 PHENYLALKYLCARBOXYLIC ACID DERIVATIVES Sankyo Company, Limited (JP) 1999-05-19 EP disclosed
EP-0708098-B1 Oxime derivatives, their preparation and their therapeutic use SANKYO CO (JP) 1999-03-03 EP disclosed
EP-0708098-A1 Oxime derivatives, their preparation and their therapeutic use SANKYO COMPANY LIMITED (JP) 1996-04-24 EP disclosed